Merck reported Q4 FY 2015 earnings of $0.93 per share (versus $0.87 in Q4 FY 2014), beating analysts' consensus of $0.91.
The company's quarterly revenues amounted to $10.215 bln (-2.5% y/y), missing consensus estimate of $10.355 bln.
Merck also issued downside guidance for FY 2016, projecting EPS of $3.60-3.75 versus analysts' consensus of $3.72 and revenues of $38.7-40.2 bln versus analysts' consensus of $40.15 bln.
MRK fell to $49.20 (-2.40%) in pre-market trading.